Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 21, Pages 3531-3540Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.27.4787
Keywords
-
Categories
Funding
- Howard Hughes Medical Institute
- NIHK08 Career Development Award
Ask authors/readers for more resources
Biliary tract cancers (BTC), which encompass intra-and extrahepatic cholangiocarcinomas and gallbladder carcinomas, are a genetically diverse collection of cancers. Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in BTC. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored. Here, we summarize the molecular pathogenesis and genetics of BTCs and animal modeling and relate these to recent and ongoing clinical trials with targeted agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available